Infectious Diseases (all articles) | Page 94 of 298 | Links Medicus Content Curation & Alerts in Medicine

Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging.

25 Aug, 2021 | 08:59h | UTC

Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging (EUSOBI) – Insights into Imaging

Covid-19: Schedule breast screening before vaccine or 4 to 6 weeks after to avoid false positives, says guidance

2 Case Series and Guidance| Lymphadenopathy in COVID-19 Vaccine Recipients

COVID-19 vaccine-linked adenopathies could mimic breast malignancies

Third Pfizer dose 86% effective in over 60s, Israeli HMO says.

25 Aug, 2021 | 09:01h | UTC

Third Pfizer dose 86% effective in over 60s, Israeli HMO says – Reuters

Commentary on Twitter

A third dose of Pfizer (PFE.N)/BioNTech's (https://t.co/eeCVHZYuCn) COVID-19 vaccine was found to be 86% effective in people aged over 60, an Israeli healthcare provider said on Wednesday, citing initial results from a study of thousands of members. https://t.co/BQMzYmMHUt

— Reuters Health (@Reuters_Health) August 18, 2021

Perspective | That ‘damn machine’: the dark side of mechanical ventilators in the ICU.

25 Aug, 2021 | 09:04h | UTC

That ‘damn machine’: the dark side of mechanical ventilators in the ICU – STAT

Systematic review: The impact of COVID-19 lockdown on child and adolescent mental health.

25 Aug, 2021 | 08:58h | UTC

The impact of COVID-19 lockdown on child and adolescent mental health: systematic review – European Child & Adolescent Psychiatry

Related: M-A: Child and youth mental health problems have doubled during COVID-19. (several articles on the subject)

Covid-19 booster vaccines: What we know and who’s doing what.

24 Aug, 2021 | 10:04h | UTC

Covid-19 booster vaccines: What we know and who’s doing what – The BMJ

WHO head calls for two-month vaccine booster moratorium.

24 Aug, 2021 | 10:02h | UTC

WHO head calls for two-month vaccine booster moratorium – Associated Press

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

24 Aug, 2021 | 10:06h | UTC

RCT: Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19 – Together Clinical Trials

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Commentary on Twitter

@TogetherTrial Manuscript Pre-print regarding #Fluvoxamine for early #COVID19 is online athttps://t.co/teHqMlowld
demonstrating ~30% relative reduction in ER visits / hospitalizations with fluvoxamine 100mg 2x/day in a 10-site, double-blind randomized trial. #IDtwitter pic.twitter.com/727by0lqft

— David Boulware, MD MPH (@boulware_dr) August 23, 2021

How will Delta evolve? Here’s what the theory tells us.

24 Aug, 2021 | 09:58h | UTC

How will Delta evolve? Here’s what the theory tells us – The Conversation

Opinion | The FDA really did have to take this long – “If vaccine approval feels maddeningly scrupulous, that’s because the alternative is worse”.

24 Aug, 2021 | 10:01h | UTC

The FDA Really Did Have to Take This Long – The Atlantic

Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience – “Despite negligible fatality, complications including hospitalization, hypoxemia, and pneumonia were more frequent in children and adolescents with COVID-19 than with influenza”.

24 Aug, 2021 | 09:51h | UTC

Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience – Pediatrics

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

AAP Guidance: Post-COVID-19 conditions in children and adolescents.

Cohort study: Risk factors for long covid in previously hospitalized children.

Cohort study: Neurological manifestations of SARS-CoV-2 infection in hospitalized children and adolescents in the UK – “around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection”.

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Deaths from COVID ‘incredibly rare’ among children.

[Preprint] Study confirms children’s extremely low risk of death from Covid-19 – “99·995% of children and young people with a positive SARS-CoV-2 test survived”.

Perspective | How should schools and daycare treat colds in the covid age? It’s complicated. – “Will every sniffle and cough be treated as potential Covid until proven otherwise?”.

24 Aug, 2021 | 09:53h | UTC

How Should Schools And Daycare Treat Colds In The Covid Age? It’s Complicated. – Romper

How I Do It: Considering lung transplantation for patients with COVID-19.

24 Aug, 2021 | 09:55h | UTC

How I Do It: Considering lung transplantation for patients with COVID-19 – CHEST

Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries

Report: Lung transplantation for 3 patients with severe COVID-19

COVID vaccines protect against Delta, but their effectiveness wanes.

24 Aug, 2021 | 09:57h | UTC

COVID vaccines protect against Delta, but their effectiveness wanes – Nature

Original study: [Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.

Guideline for immunizations in patients with inflammatory bowel disease.

24 Aug, 2021 | 09:00h | UTC

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines – Gastroenterology

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccine – Gastroenterology

Cluster RCT: Effects of a large-scale social media advertising campaign on holiday travel and COVID-19 infections.

23 Aug, 2021 | 00:01h | UTC

Effects of a large-scale social media advertising campaign on holiday travel and COVID-19 infections: a cluster randomized controlled trial – Nature Medicine

Commentary on Twitter

Even though we are tired, we should continue trying to educate the public through social media – “Social media messages recorded by health professionals before the winter holidays in the US led to a significant reduction in holiday travel and subsequent COVID-19 infections” https://t.co/kyeKTe4sJn

— gilberto lopes (@GlopesMd) August 22, 2021

Among patients receiving mRNA vaccines, clinically significant symptoms were more frequent following dose 2, following dose 1 in patients with previous SARS-CoV-2 infection, and in those who received the Moderna vaccine.

22 Aug, 2021 | 23:54h | UTC

Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers – JAMA Internal Medicine

Commentary on Twitter

New @JAMA_current paper says @moderna_Tx caused 2.3x the number of "significant" symptoms compared to @pfizer in a sample of 950 people.

Moderna also produced more antibodies. Raising the question of what a third dose, which produces still MORE, will do.https://t.co/drvhhsnpHo

— Alex Berenson (@AlexBerenson) August 16, 2021

[Preprint] Study shows symptomatic breakthrough infections are probably less transmissible than SARS-CoV-2 infections in unvaccinated individuals.

22 Aug, 2021 | 23:59h | UTC

Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study – medRxiv

Commentary on Twitter (thread – click for more)

Did you hear vaccinated people with Delta “have just as much virus in their nose so are just as infectious as unvaccinated”?

Turns out vaccinated people have significantly less culturable virus present at the same Ct count

They are LESS INFECTIOUS 💥 https://t.co/OX0Ul0ntWc pic.twitter.com/3vDQSJ6j84

— Alasdair Munro (@apsmunro) August 22, 2021

RCT: Awake prone positioning reduces the need for intubation in patients with COVID-19.

23 Aug, 2021 | 00:03h | UTC

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial – The Lancet Respiratory Medicine

Invited commentary: Awake prone positioning in COVID-19: is tummy time ready for prime time?

RCT: Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19 – no difference in intubation rates compared to standard care.

M-A: Prone positioning of nonintubated patients with Covid-19 improve oxygenation variables without any reported serious adverse events – randomized trials with patient-relevant outcomes such as the need for intubation or mortality rates are required

Commentary on Twitter

Awake prone positioning of pts w/ hypoxaemic respiratory failure due to #COVID19 reduces incidence of treatment failure & need for intubation w/o any signal of harm

Meta-trial from the Awake Prone Positioning Meta-Trial Group https://t.co/GuDdjPnVps pic.twitter.com/ZS08uQN1gE

— The Lancet Respiratory Medicine (@LancetRespirMed) August 21, 2021

Evidence mounts that people with breakthrough infections can spread Delta easily.

22 Aug, 2021 | 23:57h | UTC

Evidence mounts that people with breakthrough infections can spread Delta easily – National Geographic

Original study: Shedding of Infectious SARS-CoV-2 Despite Vaccination when the Delta Variant is Prevalent – Wisconsin, July 2021 – medRxiv

Commentary on Twitter

The evidence that supports Delta breakthrough infections ability to spread (and why fully vaccinated people need to 😷 up)https://t.co/27NOf6mYCM @NatGeo by @Ecquis w/ studies and input by @GuptaR_lab and @KasenRiemersma

— Eric Topol (@EricTopol) August 20, 2021

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

22 Aug, 2021 | 23:51h | UTC

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study – The Lancet Respiratory Medicine

Invited Commentary: Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)

Commentary on Twitter

NEW Research—Heterologous ChAdOx1 nCov-19–BNT162b2 immunisation w/ 10–12-week interval is well tolerated & improves immunogenicity vs homologous ChAdOx1 nCov-19 vax w/ 10–12-week interval & BNT162b2 vax w/ 3-week interval

Study from Prof Sander & co https://t.co/VAB54NokSi pic.twitter.com/wfeBsvoKhO

— The Lancet Respiratory Medicine (@LancetRespirMed) August 13, 2021

Study Commentaries: Non-invasive ventilation for COVID 19 patients. The Recovery RS trial.

22 Aug, 2021 | 23:52h | UTC

Commentary 1: JC: Non-invasive ventilation for COVID 19 patients. The Recovery RS trial – St Emlyn’s

Commentary 2: An adaptive randomized controlled trial of non-invasive respiratory strategies in acute respiratory failure patients with COVID-19 – The Bottom Line

Original study: [Preprint] RCT: non-invasive respiratory strategies in acute respiratory failure in patients with COVID-19 – CPAP reduced the composite outcome of intubation or death within 30 days; high-flow nasal oxygenation was not associated with better outcomes.

CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil – Effectiveness against symptomatic disease was 46.8%, 55.5% against hospitalization, and 61.2% against deaths.

22 Aug, 2021 | 23:48h | UTC

Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study – The BMJ

Editorial: Real world effectiveness of covid-19 vaccines

Related: CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness. (several texts on the subject)

[Preprint] SARS-CoV-2 aerosol transmission in schools: theoretical effectiveness of different interventions – “Combined interventions (i.e., natural ventilation, masks, and HEPA filtration) were the most effective (≥ 30-fold decrease)”.

22 Aug, 2021 | 23:50h | UTC

SARS-CoV-2 aerosol transmission in schools: the effectiveness of different interventions – medRxiv

Commentaries on Twitter

Interesting modelling study for schools: (theoretically) most effective is open windows, then masks, then HEPA filter. Would be good to do real world tests though. https://t.co/MDFNqNNUI3 pic.twitter.com/xGSodClipO

— Paul Glasziou (@PaulGlasziou) August 21, 2021

This is not real evidence supporting real policy choices as they are really carried out in the real world.

Instead, this is theoretical bioplausibility spun into a full paper.

I hope folks can still tell the two aparthttps://t.co/znwtiaKZ2g

— Vinay Prasad MD MPH (@VPrasadMDMPH) August 20, 2021